S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
The single greatest medical breakthrough of all time? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NASDAQ:KTRA

Kintara Therapeutics (KTRA) Stock Forecast, Price & News

$3.34
-0.04 (-1.18%)
(As of 06/9/2023 ET)
Compare
Today's Range
$3.31
$3.48
50-Day Range
$2.77
$4.36
52-Week Range
$2.70
$20.00
Volume
5,352 shs
Average Volume
21,688 shs
Market Capitalization
$5.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

KTRA stock logo

About Kintara Therapeutics (NASDAQ:KTRA) Stock

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Receive KTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTRA Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Trade Smarter: Discover Hidden Opportunities w/ A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
10 Pump and Dump Stocks Hedge Funds Like
See More Headlines

KTRA Price History

KTRA Company Calendar

Last Earnings
5/11/2023
Today
6/09/2023
Fiscal Year End
6/30/2023
Next Earnings (Estimated)
9/26/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KTRA
Employees
4
Year Founded
N/A

Profitability

Net Income
$-22,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.58) per share

Miscellaneous

Free Float
1,619,000
Market Cap
$5.65 million
Optionable
Not Optionable
Beta
0.93

Key Executives

  • Robert E. Hoffman
    Chairman, President & Chief Executive Officer
  • Greg A. Johnson
    Head-Operations
  • Scott Praill
    Chief Financial Officer & Secretary
  • Dennis M. Brown
    Chief Scientific Officer













KTRA Stock - Frequently Asked Questions

Should I buy or sell Kintara Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KTRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KTRA, but not buy additional shares or sell existing shares.
View KTRA analyst ratings
or view top-rated stocks.

How have KTRA shares performed in 2023?

Kintara Therapeutics' stock was trading at $6.89 at the beginning of 2023. Since then, KTRA shares have decreased by 51.5% and is now trading at $3.34.
View the best growth stocks for 2023 here
.

When is Kintara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our KTRA earnings forecast
.

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) issued its quarterly earnings results on Thursday, May, 11th. The company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $1.84.

When did Kintara Therapeutics' stock split?

Kintara Therapeutics's stock reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

What is Kintara Therapeutics' stock symbol?

Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA."

Who are Kintara Therapeutics' major shareholders?

Kintara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Susquehanna International Group LLP (0.63%). Insiders that own company stock include Anthony Scott Praill, Laura L Johnson and Saiid Zarrabian.
View institutional ownership trends
.

How do I buy shares of Kintara Therapeutics?

Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kintara Therapeutics' stock price today?

One share of KTRA stock can currently be purchased for approximately $3.34.

How much money does Kintara Therapeutics make?

Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $5.65 million. The company earns $-22,660,000.00 in net income (profit) each year or ($11.04) on an earnings per share basis.

How can I contact Kintara Therapeutics?

Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685.

This page (NASDAQ:KTRA) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -